56 results about "Inflammatory bowel disease drug" patented technology

Isoalantolactone derivatives and their application in preparation of drugs for treating inflammatory bowel diseases are provided, and an isoalantolactone derivative shown as in formula (I) is provided; a salt-forming acid is an inorganic acid or organic acid, the inorganic acid is selected from hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, carbonic acid, bromic acid, seleninic acid, phosphomolybdic acid, phosphorus acid and sulfurous acid, and the organic acid is selected from citric acid, maleic acid, D-malic acid, L-malic acid, DL-malic acid, L-lactic acid, D-lactic acid, DL-acid, oxalic acid, methylsulfonic acid, pentanoic acid, oleic acid, lauric acid, p-methylbenzene sulfonic acid, 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, phthalic acid, tartaric acid, malonic acid, succinic acid, fumaric acid, glycolic acid, mercapturic acid, glycine, creatine, sulfonic acid, nicotinic acid, picolimic acid, isonicotinic acid, and benzoic acid or substituted benzoic acid.

An application of chrysopolyose in preparing medicines to treat inflammatory enteropathy is disclosed. A process for preparing chrysopolyose includes such steps as pulverizing rhubarb, removing liposoluble component, refluxing extraction with distilled water, concentrating, deposition, decolouring, removing protein by the freeze-thaw method several times then by the sevag method several times. determining by stags saccharide content, dialysis, filtering, concentrating, freeze-drying and depositing by stages in absolute alcohol.

The invention relates to new application of schisandra chinensis total polysaccharide in preparation of medicines or health products for treating inflammatory bowel diseases, in particular to new application in preparation of medicines or health products for treating ulcerative colitis (UC), Crohn disease (CD) and acute and chronic intestinal diseases. Experiments show that the schisandra chinensis total polysaccharide can significantly improve inflammatory injury of colon, reduce spleen indexes, increase thymus indexes, effectively reduce the contents (activity) of MPO, NO, MDA and ROS in thecolons, and increase the contents of GSH and SOD at the same time. Meanwhile, the schisandra chinensis polysaccharide regulates the composition and diversity of intestinal microorganisms of colitis mice, obviously improves the relative abundance of Finnicutes, sugar bacteria, Enterorhabdus and the like, reduces the relative abundance of intestinal bacteria such as Firmicutes, Turicibacter and Akkermansia, remarkably increases the contents of propionic acid, butyric acid and isobutyric acid in the colon, and it is prompted that the schisandra chinensis total polysaccharide can be used for preparing medicines for treating or improving inflammatory bowel diseases.

The present invention relates to an andrographolide enteric targeting micropellet and a method for preparation thereof; furthermore, the present invention also relates to uses of andrographolide and andrographolide enteric targeting micropellets in preparation of a pharmaceutical for treatment of inflammatory bowel disease.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a novel pharmaceutical application of Houttuynia cordata Thunb. polysaccharide, in particular to the application of the Houttuynia cordata Thunb. polysaccharide in preparation of a medicine for preventing and treating inflammatory bowel disease (IBD). A total polysaccharide extract is separated and extracted from the traditional Chinese medicine Houttuynia cordata Thunb., the average product yield is 3.65%, and the polysaccharide content exceeds 70%. An integral experiment proves that the total polysaccharide extract of the Houttuynia cordata Thunb. has a remarkable treatment effect on mouse colonic injury induced by 2.5% DSS. The Houttuynia cordata Thunb. polysaccharide may inhibit infiltration of inflammatory cells, reduce secretion of inflammatory cytokines and inhibit expression of an inflammatory transcription factor NF [kappa] B through an anti-inflammatory mechanism of the Houttuynia cordata Thunb. polysaccharide, so that intestinal injury is reduced, intestinal mucosa is protected, and colon shortening and weight loss are relieved. The Houttuynia cordata Thunb. polysaccharide can be used for preparing medicines for preventing and treating ulcerative colitis.

The invention creatively provides an application of typhagoside in preparation of a medicine for treating inflammatory bowel diseases. According to the application disclosed by the invention, a DSS-induced C57BL/6J mouse colitis model is treated by the typhagoside. Inflammation-related parameters such as weight loss, disease activity index and spleen weight of a mouse are improved, histological staining reveals that intestinal inflammation of the mouse is inhibited, and the pathological score is reduced. By further investigating a specific mechanism of anti-inflammatory effect, the result shows that the typhagoside can inhibit activation of an NF-kB pathway in mouse intestinal epithelial cells and reduce expression of inflammatory factors in the mouse intestinal epithelial cells. In conclusion, the Chinese herbal monomer typhagoside can provide a new way for preparing medicines for treating IBD and related diseases thereof in the future.

The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohn's disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patient's pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.

The present invention relates to a therapeutic agent for inflammatory bowel disease comprising 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione or a pharmaceutically acceptable salt thereof as an active ingredient.

According to the present invention, an effective and safe therapeutic agent for inflammatory bowel disease including ulcerative colitis and Crohn's disease can be provided. The balance between the therapeutic effect on a chronic inflammation such as inflammatory bowel disease and the adverse side effect of the compound is superior to those of an aminosalicylic acid preparation and a corticosteroid preparation, which cannot be expected at all from a mere anti-diarrheal effect.

The invention discloses an application of a pueraria flower extract in preparation of drugs for preventing, treating and relieving inflammatory bowel diseases, protecting intestinal barriers and stabilizing intestinal morphology, provides a reliable anti-inflammatory agent to help to maintain the balance of the intestinal environment, and has the advantages of good curative effect on the inflammatory bowel diseases, low price and no obvious side effect. The invention finds and verifies that the pueraria flower extract has a remarkable curative effect on inflammatory bowel diseases, is low in price and side effect, and can macroscopically improve the intestinal inflammation state by improving the body health level, reducing the intestinal permeability, prolonging the intestinal length and the like. The pueraria flower extract can relieve excessive proliferation and differentiation of precursor cells caused by exogenous proinflammatory factors by negatively regulating an important factor, namely a JAK-STAT signal channel, of a colitis pathogenesis and maintain the homeostasis of intestinal cells, so that the effect of treating the inflammatory bowel disease is achieved.

The invention discloses an application of a kaurane compound in preparation of a medicine for treating inflammatory bowel disease. The kaurane compound can obviously reduce the weight of a dextran sodium sulfate induced (DSS) enteritis model mouse, improve the shortening of the colon length of the colitis model mouse, relieve the infiltration of colon tissue inflammatory cells of the colitis model mouse, reduce the rise of leukocytes, neutrophils, lymphocytes and monocytes of the colitis model mouse, reduce the expression of inflammatory factors, and achieve the immunoregulation function on intestinal tracts. The mechanism of the kaurane compound may be known by adjusting polarization of macrophages and differentiation of T cells, and the kaurane compound can relieve the inflammatory reaction of DSS-induced inflammatory bowel disease model mice and improve the severity of the inflammatory bowel disease, and can be used for preparing drugs or health care products for treating the inflammatory bowel disease.

The invention provides application of Alistipes putredinis bacteria in preparation of a medicine for preventing and treating inflammatory bowel diseases, and relates to the technical field of biological medicines. A C57BL/6 mouse colitis model is adopted, and it is found that the A.putredinis bacterium can improve intestinal inflammation of DSS mice. It is confirmed for the first time that A.putredinis can inhibit intestinal inflammation of mice with DSS colitis, a new theory is provided for pathogenesis of CD, a new treatment strategy is provided for CD diagnosis and treatment, and potential clinical application prospects are achieved.

The invention discloses application of sodium p-hydroxybenzoate in preparation of a medicine for treating or preventing inflammatory bowel diseases. Under the condition that the dosage is obviously lower than that of mesalazine, sodium p-hydroxybenzoate can obviously inhibit the increase of the disease activity index score of enteritis model mice induced by dextran sodium sulfate, improve the contraction in length of colons of colitis model mice, reduce the MPO activity of the colons of the mice, and relieve inflammatory cell infiltration of colons of the colitis model. The invention also discloses a medicine for treating or preventing inflammatory bowel diseases. Sodium p-hydroxybenzoate is used as an effective component of the medicine and the medicine contains an effective dose of sodium p-hydroxybenzoate in treatment.